stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) Net margin
Praxis Precision Medicines, Inc.'s net margin over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −5,037.9% (fiscal 2023) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 2,137.48 |
| FY2024 | −2,137.5% | 2,900.40 |
| FY2023 | −5,037.9% | (5,037.88) |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 0.00% | 0.00 |
| Mar 2026 | 0.00% | 0.00 |
| Dec 2025 | 0.00% | 0.00 |
| Sep 2025 | 0.00% | 0.00 |
| 23 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 47.9% |
| CORT Corcept Therapeutics Incorporated compare | 16.5% |
| PRAX Praxis Precision Medicines, Inc. | 0.00% |
| ABVX Abivax SA Sponsored ADR compare | 0.00% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| AXSM Axsome Therapeutics, Inc. compare | −18.2% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −47.8% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −70.6% |
| CYTK Cytokinetics, Incorporated compare | −686.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue